{"id":"NCT02248961","sponsor":"R-Pharm","briefTitle":"Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension","officialTitle":"Open-label, Randomized, Multicenter, Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan), Manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, Tablets 60/120 mg and Cozaar® (Losartan), Manufactured by MERCK SHARP & DOHME B.V., Netherlands, Tablet 50/100 mg in Adult Patients With Grade I-II Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2014-09-25","resultsPosted":"2019-05-06","lastUpdate":"2019-05-06"},"enrollment":179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Fimasartan","otherNames":["Kanarb"]},{"type":"DRUG","name":"Losartan","otherNames":["Cozaar®"]}],"arms":[{"label":"Kanarb (Fimasartan)","type":"EXPERIMENTAL"},{"label":"Cozaar® (Losartan)","type":"ACTIVE_COMPARATOR"}],"summary":"Assess and compare the efficacy and safety of Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP \\& DOHME B.V., Netherlands, tablet 50/100 mg in adult patients with Grade I-II arterial hypertension in 12 weeks of therapy","primaryOutcome":{"measure":"Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment","timeFrame":"Baseline and week 12 of treatment","effectByArm":[{"arm":"Kanarb (Fimasartan)","deltaMin":152.9,"sd":5.9},{"arm":"Cozaar® (Losartan)","deltaMin":151.9,"sd":5.9}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.390"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":89},"commonTop":["Headache","Nausea","Aspartate aminotransferase increased","Nasopharyngitis","Alanine aminotransferase increased"]}}